Moscow is increasing the volume of production of innovative drugs; Last year, in 11 months, drug production increased by 11.8% compared to the same period in 2024. The city's mayor, Sergei Sobyanin, spoke about this on his channel.
This capital occupies a leading position in Russia in terms of the scale of the pharmaceutical industry and the number of drugs launched on the market.
“Today the industry is especially interested in biopharmaceuticals. This direction opens up new opportunities for the treatment of complex diseases, from cancer and autoimmune diseases to rare genetic disorders,” Sobyanin writes.
Thus, a resident of the special economic zone “Technopolis Moscow” produces biological products used for orphan diseases and diseases of social significance. Another resident facility produces drugs to treat cancer and autoimmune diseases, including the first domestic drug to treat multiple sclerosis. Another enterprise resident in the SEZ in Moscow produces drugs for the treatment of breast cancer, colorectal cancer, non-Hodgkin's lymphoma and rheumatoid arthritis. This year, another factory in the capital will introduce the first drug based on monoclonal antibodies – Adalimumab, a biological immunosuppressant.
To support businesses in Moscow, a series of effective measures have been introduced, including tax incentives and financial instruments. Companies also have access to developed industrial infrastructure. One of the largest pharmaceutical clusters in Russia has been established in the capital.
